Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 1/20 | 0.70 |
| ▸ | CA2 | P00918 | 1/20 | 0.70 |
| ▸ | CA9 | Q16790 | 1/20 | 0.70 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.68 |
| ▸ | ALDH1A1 | P00352 | 14/20 | 0.61 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | MBTD1 | Q05BQ5 | 1/20 | 0.52 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.52 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.52 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3905679 | 0.98 | CA12 (0.72) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL3898192 | 0.97 | CA12 (0.70) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7203889 | 0.97 | CA12 (0.70) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7095475 | 0.95 | CA12 (0.68) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7095728 | 0.94 | CA12 (0.66) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7205364 | 0.93 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7097556 | 0.93 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7207746 | 0.93 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7203875 | 0.93 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 | |
| SCHEMBL7092423 | 0.93 | CA12 (0.64) | CA12CA2CA9ALOX15ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9054392-B2 | Electrolyte solution and magnesium battery including the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2015-06-09 | — | — | US | disclosed |
| US-8420626-B2 | Arene connected polyamine macrocyclic derivatives, preparation methods and pharmaceutical uses thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2013-04-16 | — | — | US | disclosed |
| US-20120171577-A1 | ELECTROLYTE SOLUTION AND MAGNESIUM BATTERY INCLUDING THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2012-07-05 | — | — | US | disclosed |
| EP-2412729-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2012-02-01 | — | — | EP | disclosed |
| EP-2399938-A2 | Peptide purification by means of hard metal ion affinity chromatography | Novo Nordisk A/S (DK) | 2011-12-28 | — | — | EP | disclosed |
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | BEIJING MOLECULE SCIENCE AND TECHNOLOGY CO., LTD. (CN) | 2010-07-15 | — | — | US | disclosed |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | HEARN MILTON THOMAS WILLIAM | 2009-06-04 | — | — | US | disclosed |
| US-6084093-A | SUBSTITUTED 1,4,7,10,13-PENTAAZACYCLOPENTADECANE MACROCYCLIC LIGANDS; MANGANESE COMPLEXES OF THE LIGAND ARE MIMICS OF SUPEROXIDE DISMUTASE; USEFUL AS THERAPEUTIC AGENTS FOR INFLAMMATORY DISEASES | G. D. SEARLE & CO. (US) | 2000-07-04 | — | — | US | disclosed |
| US-5874421-A | Manganese complexes of nitrogen-containing macrocyclic ligands effective as catalysts for dismutating superoxide | G. D. SEARLE & CO. (US) | 1999-02-23 | — | — | US | disclosed |
| EP-0598753-B1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO CO (US) | 1998-03-18 | — | — | EP | disclosed |
| US-5637578-A | AGENTS FOR INFLAMMATION, ISCHEMIC/REPERFUSION INJURY, STROKE, ATHEROSCLEROSIS, AND HYPERTENSION | MONSANTO COMPANY | 1997-06-10 | — | — | US | disclosed |
| US-5610293-A | TREATMENT OF INFLAMMATORY DISEASES, ISCHEMIC/REPERFUSION INJURY, STROKE, ATHERSCLEROSIS, HYPERTENSION | MONSANTO COMPANY (US) | 1997-03-11 | — | — | US | disclosed |
| EP-0598753-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1994-06-01 | — | — | EP | disclosed |
| US-5219555-A | Coupling isotopes with macrocyclic amines; diagnosis | HOECHST AKTIENGESELLSCHAFT (DE) | 1993-06-15 | — | — | US | disclosed |
| WO-1993002090-A1 | MANGANESE COMPLEXES OF NITROGEN-CONTAINING MACROCYCLIC LIGANDS EFFECTIVE AS CATALYSTS FOR DISMUTATING SUPEROXIDE | MONSANTO COMPANY (US) | 1993-02-04 | — | — | WO | disclosed |
| EP-0524161-A1 | Manganese complexes of nitrogen containing macrocyclic ligands effective as catalysts for dismutating superoxide | MONSANTO COMPANY (US) | 1993-01-20 | — | — | EP | disclosed |
| EP-0304780-B1 | PROCESS FOR LABELLING SUBSTANCES WITH TECHNETIUM OR RHENIUM | HOECHST AKTIENGESELLSCHAFT (DE) | 1991-08-07 | — | — | EP | disclosed |
| EP-0304780-A1 | Process for labelling substances with technetium or rhenium | HOECHST AKTIENGESELLSCHAFT (DE) | 1989-03-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179116-A1 | Arene Connected Polyamine Macrocyclic Derivatives, Preparation Methods and Pharmaceutical Uses Thereof | SRM, SP1, SMS | CA12 4689/4885CA2 4341/4885CA9 4569/4885 |
| US-20090143529-A1 | Peptide purification by means of hard metal ion affinity chromatography | MAX, PTMS, SLC7A1 | CA12 1451/4885CA2 99/4885CA9 1438/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.